Tau Therapeutics, LLC IND Accepted by FDA for Novel Cancer Drug

Published: Feb 28, 2012

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

Back to news